A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis

Neurology and Therapy

Volumn 4, Issue 2, 2015, Pages 61-79

  Waddington Cruz, Márcia ^a   Benson, Merril D ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloidosis; Familial amyloid polyneuropathy; Tafamidis; Transthyretin

Indexed keywords

TAFAMIDIS;

AMYLOIDOSIS; CARDIOMYOPATHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; GENE MUTATION; HEART RATE; NERVE CONDUCTION; NEUROPATHY; NUTRITIONAL STATUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

EID: 84977080435     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-015-0031-3     Document Type: Review

References (41)

1. Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid. 2012;19(Suppl. 1):65–7.
2. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411–23.
3. Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;0:1–8.
4. Johnson ST, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory agency approved drug. J Mol Biol. 2012;421:185–203.
5. Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. PNAS. 2012;24:9629–34.
6. Berk J, Dyck P, Obici L, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid. 2011;18(Suppl. 1):191–2.
7. Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. PNAS. 2002;99:16427–32.
8. Kelly JW, Colon W, Lai Z, et al. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem. 1997;50:161–81.
9. McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry. 1995;34:13527–36.
10. McCutchen SL, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry. 1993;32:12119–27.
11. Coelho T, Carvalho M, Saraiva MJ, Alves I, Almeida MR, Costa PP. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119. J Rheumatol. 1993;20:179.
12. Coelho T, Chorao R, Sousa A, Alves I, Torres MF, Saraiva MJ. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromusc Disord. 1996;6:27.
13. Coelho T, Maia LF, da Silva AM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy. A randomized, controlled trial. Neurology. 2012;79:785–92.
14. Dyck PJ, Karnes JL, O’Brien PC, Litchy WJ, Low PA, Melton LJ 3rd. The rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164–70.
15. Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the rochester diabetic neuropathy study cohort. Neurology. 1997;49:229–39.
16. Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802–14.
17. Merilini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with Non-Val30et transthyretin amyloidosis. J Cardiovasc Trans Res. 2013;6:1011–20.
18. Coelho T, Conceição IM, Barroso F, et al. Long term effects of tafamidis treatment on transthyretin familial amyloid polyneuropathy (TTR-FAP): interim results from the Fx1A-303 study. Eur J Neurol. 2014;21(Suppl. 1):81.
19. Suhr OB, Conceição IM, Karayal ON, Mandel FS, Huertas PE, Ericzon BG. Post Hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurol Ther. 2014;3:101–12.
20. Klamerus KJ, Watsky E, Moller R, Wand R, Riley S. The effect of tafamidis on the QTc interval in heathy subjects. Br J Clin Pharmacol. 2015;79(6):918–25. doi:10.1111/bcp.12561.
21. Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015; CIRCHEARTFAILURE.113.000890published online before print April 14 2015.
22. Ruberg FL, Maurer MS, Judge DP, et al. Prospectie evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS). Am Heart J. 2012;164:222–8.
23. Safety and pharmacokinetic assessment of orally administered tafamidis in healthy volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT01994889?term=%22tafamidis%22+and+%22cardiomyopathy%22&rank=1. Safety and efficacy of tafamidis in patients with transthyretin cardiomyopathy (ATTR-ACT).
24. Adams D. Recent Advances in the treatment of familial amyloid polyneuropathy. Adv Neurol Disord. 2013;6:139–49.
25. Adams D, Cauquil C, Theaudin M, Rousseaus A, Algalarrondo V, Slama MS. Current and future treatment of amyloid neuropathies. Expert Rev Neurother. 2014;14:1437–51.
26. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho P, Costa E, Falcao de Freitas A (Eds.), Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. pp. 88–98.
27. Lozeron P, Théaudin M, Mincheva Z, Duccot B, Lacrox C, Adams D, French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20:1539–45.
28. Koike H, Ando Y, Ueda M, Kawagashira Y, Iijima M, Fujitake J, Hayashi M, Yamamoto M, Mukai E, Nakamura T, Katsuno M, Hattori N, Sobue G. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30 Met familial amyloid polyneuropathy. J Neurol Sci. 2009;287:178–84.
29. Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G. Pathology of early- versus late-onset TTR Met30 familial amyloid polyneuropathy. Neurology. 2004;63(1):129–38.
30. Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.
31. Seikijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39:225–33.
32. Obici L, Merlini G. An overview of drugs current under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs. 2014;23:1239–51.
33. Barbosa da Silva RV, Cruz MW, Planté-Bordeneuve V. Follow-up of transthyretin amyloidosis patients with liver transplants or receiving tafamidis treatment as documented in THAOS: the transthyretin amyloidosis outcomes survey. Poster presented at the 16th Congress of the European Federation of Neurological Societies. Stockholm, Sweden, 8–11, 2012. P 2918.
34. Coelho T, Conceição I, Cardoso M, et al. Evaluation of 1 year treatment with tafamidis in Portuguese patients with transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2014;21(Suppl. 1):327.
35. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
36. Maia LF, Magalhães R, Freitas J, Taipa R, Pires MM, Osório H, Dias D, Pessegueiro H, Correia M, Coelho T. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015;86(2):159–67. doi:10.1136/jnnp-2014-308107(Epub 2014 Aug 4).
37. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, Uchino M, Suhr OB. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl. 2009;15:1229–35.
38. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid. 2011;18:53–62.
39. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. Jama. 2013;310(24):2658–2667. Prepublished on 2013/12/26 as doi:10.1001/jama.2013.283815. PMID24368466.
40. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–29.
41. Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. PNAS. 2002;99:16427–32.